InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,302.71
(
0.34%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: lax20m post# 6646

Tuesday, 03/29/2011 2:15:17 PM

Tuesday, March 29, 2011 2:15:17 PM

Post# of 80490
imo, at current levels, ARIA still offers the most upside (on a risk-adjusted basis). fwiw, back of the envelope - here are the targets I've had for over a year:

$6 to $8 pre-Rida filing
$8 to $10 post-filing
$12 upon rida approval.
add $3 for ponatinib at NDA and $8 at approval.

2011 target is right around $12.
2012 target is $18 to $20 with the ALK inhibitor the wildcard.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up